Tuccatinn 150mg Bulk Export to South Africa | Ernest Oncology India

Tuccatinn 150mg Tablet: Advanced Targeted Therapy for HER2-Positive Oncology Care

Are you looking for a trusted Tuccatinn 150 mg tablet exporter from India? Ernest Oncology, a specialized division of Ernest Pharmaceutical Pvt. Ltd., is a premier global supplier and bulk distributor of advanced targeted therapies. We maintain a high-authority, regulatory-compliant supply chain serving the UK (London), USA, Australia, and South Africa, ensuring that life-saving medications reach healthcare providers with pharmaceutical-grade integrity and efficient global logistics.

Detailed Product Overview: What is Tuccatinn 150mg?

Tuccatinn 150mg is a high-potency oral targeted therapy containing the active pharmaceutical ingredient Tucatinib. Developed as a highly selective Tyrosine Kinase Inhibitor (TKI), it specifically targets the HER2 (Human Epidermal Growth Factor Receptor 2) protein.

Unlike many other therapies, Tuccatinn is engineered to cross the blood-brain barrier, making it a pivotal treatment option for patients whose cancer has spread to the central nervous system. Manufactured by BDR Pharmaceuticals in India, Tuccatinn 150mg provides a world-class, cost-effective alternative for global oncology procurement, meeting the highest international standards for quality and efficacy.

Primary Therapeutic Indications

Tuccatinn 150 mg is clinically indicated for the management of:

1. Metastatic HER2-Positive Breast Cancer: For adult patients who have received one or more prior anti-HER2-based regimens. It is typically used in a "triplet" combination with Trastuzumab and Capecitabine.

2. Brain Metastases: It is highly effective in treating HER2-positive breast cancer that has spread to the brain, a condition traditionally difficult to treat with standard monoclonal antibodies.

3. HER2-Positive Colorectal Cancer: In specific clinical settings, it is used in combination with Trastuzumab for adult patients with RAS wild-type HER2-positive unresectable or metastatic colorectal cancer.

Mechanism of Action: How Tuccatinn 150mg Works

Tuccatinn operates through a sophisticated intracellular mechanism:

• Selective HER2 Inhibition: It binds to the intracellular kinase domain of the HER2 receptor. This prevents the phosphorylation and subsequent signaling pathways (like MAPK and PI3K/Akt) that tell cancer cells to grow and divide.

• Superior Selectivity: It is designed to be highly selective for HER2 over EGFR (Epidermal Growth Factor Receptor), which potentially reduces common side effects like severe skin rash and diarrhea often seen with less selective inhibitors.

• Brain Penetration: Its unique chemical structure allows it to reach therapeutic concentrations in the cerebrospinal fluid, directly attacking tumor cells within the brain.

Administration and Safety Guidelines

• Standard Dosage: The typical dose is 300 mg (two 150 mg tablets) taken orally twice daily (approximately 12 hours apart), with or without food.

• Instructions: Tablets must be swallowed whole. Do not chew, crush, or split the tablets. If a dose is missed or vomiting occurs, do not take an extra dose; proceed with the next scheduled dose.

• Key Precautions:

• Hepatotoxicity: Regular liver function tests (ALT, AST, and bilirubin) are required every 3 weeks during treatment.

• Diarrhea Management: Severe diarrhea can occur. Patients are advised to keep antidiarrheal medication (like loperamide) available and increase fluid intake.

• Embryo-Fetal Toxicity: Tuccatinn can cause fetal harm. Effective contraception is mandatory for both female and male patients during and for at least one week after the final dose.

• 
  

Why Source Tuccatinn 150 mg from Ernest Oncology?

• Strategic Indian Exporter: Direct access to BDR Pharmaceuticals’ manufacturing excellence, ensuring 100% authenticity and competitive bulk pricing for the international market.

• Expertise in Complex Logistics: Proven track record in navigating cold chain and regulatory requirements for the UK, USA, Australia, and South Africa.

• Global Supply Continuity: We specialize in bulk fulfillment for oncology hospitals and government tenders, ensuring no interruption in patient treatment cycles.

• Regulatory Compliance: Every shipment is accompanied by the necessary COA (Certificate of Analysis) and documentation for seamless customs clearance.